Global Markets Direct’s, 'Enterobacteriaceae Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterobacteriaceae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterobacteriaceae Infections. Enterobacteriaceae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Enterobacteriaceae Infections. - A review of the Enterobacteriaceae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterobacteriaceae Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Enterobacteriaceae Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Enterobacteriaceae Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Enterobacteriaceae Infections - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Enterobacteriaceae Infections Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Enterobacteriaceae Infections 7 Enterobacteriaceae Infections Therapeutics under Development by Companies 9 Mid Clinical Stage Products 11 Comparative Analysis 11 Discovery and Pre-Clinical Stage Products 12 Comparative Analysis 12 Enterobacteriaceae Infections Therapeutics - Products under Development by Companies 13 Companies Involved in Enterobacteriaceae Infections Therapeutics Development 14 Achaogen Inc. 14 Trana Discovery, Inc. 15 Da Volterra 16 Enterobacteriaceae Infections - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Drug Profiles 22 plazomicin - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 RX-04 - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 RX-P792 - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 Gram Negative Antibacterial Programs - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 Metallo-Beta-Lactamase Inhibitors - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 DAV-121 - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 NOSO-74 - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 NAB-741 - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 NAB-7061 - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 Enterobacteriaceae Infections Therapeutics - Drug Profile Updates 36 Enterobacteriaceae Infections Therapeutics - Discontinued Products 39 Enterobacteriaceae Infections Therapeutics - Dormant Products 40 Enterobacteriaceae Infections - Product Development Milestones 41 Featured News and Press Releases 41 Sep 23, 2013: Achaogen Announces Agreement With FDA on a Special Protocol Assessment for a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) 41 Apr 24, 2013: Achaogen Receives $60m Contract Option From BARDA For Clinical Development Of Plazomicin 41 Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CXA-201 At ICAAC 2012 42 May 03, 2011: Rib-X Pharma To Present Three Posters On Its RX-04 Development Program At 21st ECCMID/ 27th ICC 42 Jan 06, 2011: NovaBay Reports Activity Of NVC-422 Against Deadly Superbug Producing NDM-1 43 Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables
Number of Products Under Development for Enterobacteriaceae Infections, H2 2013 7 Products under Development for Enterobacteriaceae Infections - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 10 Comparative Analysis by Mid Clinical Stage Development, H2 2013 11 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12 Products under Development by Companies, H2 2013 13 Achaogen Inc., H2 2013 14 Trana Discovery, Inc., H2 2013 15 Da Volterra, H2 2013 16 Assessment by Monotherapy Products, H2 2013 17 Assessment by Stage and Route of Administration, H2 2013 19 Assessment by Stage and Molecule Type, H2 2013 21 Enterobacteriaceae Infections Therapeutics - Drug Profile Updates 36 Enterobacteriaceae Infections Therapeutics - Discontinued Products 39 Enterobacteriaceae Infections Therapeutics - Dormant Products 40
List of Figures
Number of Products under Development for Enterobacteriaceae Infections, H2 2013 7 Products under Development for Enterobacteriaceae Infections - Comparative Analysis, H2 2013 8 Products under Development by Companies, H2 2013 9 Mid Clinical Stage Products, H2 2013 11 Discovery and Pre-Clinical Stage Products, H2 2013 12 Assessment by Monotherapy Products, H2 2013 17 Assessment by Route of Administration, H2 2013 18 Assessment by Stage and Route of Administration, H2 2013 19 Assessment by Molecule Type, H2 2013 20 Assessment by Stage and Molecule Type, H2 2013 21